Shanghai, January 12, 2020– Laekna Therapeutics, a clinical-stage biotech company focused on innovative drug development and discovery, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square.

Dr. Chris Lu, the founder and CEO of Laekna, will be presenting an update on Laekna’s business strategy and the progress of its clinical programs including afuresertib, an AKT inhibitor, at Biotech Showcase as follows:

Date: Wednesday, January 15 2020

Time: 11:00AM (PST)

Room: Franciscan C (Ballroom Level)

Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)

Laekna currently has three clinical stage oncology candidates in-licensed from Novartis covering targeted, anti-hormone, and immune therapies. These compounds have been extensively studied previously in a number of phase I & II clinical trials and have demonstrated excellent anti-cancer activities and tolerable safety profiles.

"We are excited to present the progress of our clinical programs at Biotech Showcase™," said Dr. Chris Lu. “This will be a good opportunity to introduce Laekna’s key clinical programs to pharmaceutical community. We are actively seeking opportunities to collaborate with potential investors and business partners and quickly advance the programs through the clinical stage to help patients."

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.